KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Goodwill: 2009-2024

Historic Goodwill for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $15.1 billion.

  • Teva Pharmaceutical Industries' Goodwill fell 1.11% to $15.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 billion, marking a year-over-year decrease of 1.11%. This contributed to the annual value of $15.1 billion for FY2024, which is 11.82% down from last year.
  • As of FY2024, Teva Pharmaceutical Industries' Goodwill stood at $15.1 billion, which was down 11.82% from $17.2 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Goodwill registered a high of $20.6 billion during FY2020, and its lowest value of $15.1 billion during FY2024.
  • For the 3-year period, Teva Pharmaceutical Industries' Goodwill averaged around $16.5 billion, with its median value being $17.2 billion (2023).
  • Data for Teva Pharmaceutical Industries' Goodwill shows a maximum YoY fell of 16.99% (in 2020) over the last 5 years.
  • Teva Pharmaceutical Industries' Goodwill (Yearly) stood at $20.6 billion in 2020, then decreased by 14.50% to $17.6 billion in 2021, then declined by 2.59% to $17.2 billion in 2022, then remained steady at $17.2 billion in 2023, then decreased by 11.82% to $15.1 billion in 2024.